What is a Decipher test?
The Decipher® test is a tissue-based prostate cancer marker (PCM) that helps inform the decision of treatment vs. active surveillance in patients with low to intermediate grade prostate cancer confined to the prostate.
Also known as Decipher Biopsy, this genomic test analyzes individual tumor aggressiveness and combines it with an individual’s clinically validated prostate cancer-specific mortality risk and personal risk of metastasis. Using advanced whole genome technology, Decipher Biopsy provides valuable insights to make more informed decisions about next steps in managing prostate cancer.
Learn more about how the Decipher test predicts prostate cancer-specific risk, metastasis, and mortality.
Understanding Your Decipher Biopsy Test Results
The Decipher Biopsy test was designed for individuals with low, favorable intermediate, and unfavorable intermediate risk prostate cancer (less than or equal to Gleason 4+3=7) who are uncertain if they should get treatment or pursue active surveillance. See a sample Decipher result report and learn about how to interpret this report.
Below is an initial list of frequently asked questions about the Decipher test. You can also submit your question.
Prostate cancer biomarkers (PCMs) are molecules found in blood, tissue, or body fluids. PCMs are revolutionary new, non-invasive diagnostic tests that may help your healthcare provider decide if your prostate cancer is in fact low risk, if something more aggressive may be lurking in your prostate, or if there are hot spots in the prostate that may need to be re-evaluated upon biopsy. PCMs also can help you and your healthcare provider determine the most appropriate treatment for your cancer.
There are many factors that will make one prostate cancer marker test better suited for individual cases. Many times, individuals who have never had a biopsy or had low to intermediate grade prostate cancer (Gleason 3+3=6 or 3+4=7) diagnosed on a biopsy are well suited for blood or urine prostate cancer markers, whereas individuals who have persistently negative biopsies or a biopsy of intermediate to high grade cancer may benefit from tissue prostate cancer markers. Use this interactive questionnaire to see what tests may be right for you. Once you’ve completed the questionnaire, discuss the results with your healthcare provider. Also be sure to check out our Patient Journey section that may help you decide which test is right for you.
If you have a negative or atypical biopsy and are wanting more insights about prostate cancer risk, you might consider the tissue-based PCM test:
If your prostate biopsy has a Gleason Score of less than or equal to 7 or if your prostate biopsy has a Gleason Score greater than 7 and you have not yet undergone treatment (surgery or radiation), you and your healthcare provider might consider these tissue-based PCM tests:
If your prostate biopsy has a Gleason Score greater than 7 and you have already undergone treatment, please see Waypoint 4 for additional PCM tests to consider.
Men who have a PSA score of less than or equal to 20 ng/ml and have organ confined, less than or equal to Gleason score of 4+3=7 prostate cancer found on biopsy could benefit from the Decipher genomic testing.
The Decipher Biopsy test analyzes 22 RNA biomarkers associated with metastatic progression including: cell cycle progression, immune system activity/response, androgen signaling, metabolism and cancer blood vessel formation potential. You should always discuss the results of your test with your physician. In general, results of the Decipher Biopsy test are presented as follows:
- Overall genomic cancer risk
- Low, intermediate or high risk
- Risk of harboring high-grade disease (0-100%) if you had prostate removal surgery
- Risk of metastasis within 5 years (0-100%)
- Risk of prostate cancer death within 10 years (0-100%)
See a sample Decipher Biopsy test report and learn more about how to read the results.
Explore more information about Decipher Biopsy.